Day One Biopharmaceuticals in the spotlight (part III)

Revised FDA timeline, competitive landscape evaluation, and other considerations

Day One DAWN 0.00%↑ announced a $150M raise priced at $13/share after presenting additional data at ASCO 2023. Importantly, the company formed a regulatory pathway in the relapsed/refractory setting, which suggests that the FDA is supportive of DAWN’s data. Investors seem confident enough in the data/path forward to participate in a financing at $13/share.

Timeline…